Logo image of PCSA

PROCESSA PHARMACEUTICALS INC (PCSA) Stock Fundamental Analysis

USA - NASDAQ:PCSA - US74275C3043 - Common Stock

0.2813 USD
+0.07 (+31.94%)
Last: 10/6/2025, 3:57:08 PM
Fundamental Rating

2

Taking everything into account, PCSA scores 2 out of 10 in our fundamental rating. PCSA was compared to 196 industry peers in the Pharmaceuticals industry. While PCSA seems to be doing ok healthwise, there are quite some concerns on its profitability. PCSA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PCSA had negative earnings in the past year.
In the past year PCSA has reported a negative cash flow from operations.
PCSA had negative earnings in each of the past 5 years.
In the past 5 years PCSA always reported negative operating cash flow.
PCSA Yearly Net Income VS EBIT VS OCF VS FCFPCSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of PCSA (-157.44%) is worse than 84.18% of its industry peers.
With a Return On Equity value of -210.93%, PCSA is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -157.44%
ROE -210.93%
ROIC N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
PCSA Yearly ROA, ROE, ROICPCSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCSA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCSA Yearly Profit, Operating, Gross MarginsPCSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for PCSA has been increased compared to 1 year ago.
The number of shares outstanding for PCSA has been increased compared to 5 years ago.
The debt/assets ratio for PCSA is higher compared to a year ago.
PCSA Yearly Shares OutstandingPCSA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PCSA Yearly Total Debt VS Total AssetsPCSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

PCSA has an Altman-Z score of -17.46. This is a bad value and indicates that PCSA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -17.46, PCSA is not doing good in the industry: 79.59% of the companies in the same industry are doing better.
PCSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -17.46
ROIC/WACCN/A
WACCN/A
PCSA Yearly LT Debt VS Equity VS FCFPCSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 3.45 indicates that PCSA has no problem at all paying its short term obligations.
PCSA has a Current ratio (3.45) which is in line with its industry peers.
A Quick Ratio of 3.45 indicates that PCSA has no problem at all paying its short term obligations.
The Quick ratio of PCSA (3.45) is better than 61.22% of its industry peers.
Industry RankSector Rank
Current Ratio 3.45
Quick Ratio 3.45
PCSA Yearly Current Assets VS Current LiabilitesPCSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

PCSA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.20%, which is quite impressive.
EPS 1Y (TTM)57.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PCSA will show a very strong growth in Earnings Per Share. The EPS will grow by 61.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.2%
EPS Next 2Y39.27%
EPS Next 3Y24.54%
EPS Next 5Y61.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCSA Yearly Revenue VS EstimatesPCSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2027 2028 2029 2030 2031 100M 200M 300M
PCSA Yearly EPS VS EstimatesPCSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 -20 40 60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PCSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCSA Price Earnings VS Forward Price EarningsPCSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCSA Per share dataPCSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as PCSA's earnings are expected to grow with 24.54% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.27%
EPS Next 3Y24.54%

More info and screens

0

5. Dividend

5.1 Amount

PCSA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (10/6/2025, 3:57:08 PM)

0.2813

+0.07 (+31.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)10-28 2025-10-28
Inst Owners0.74%
Inst Owner Change0%
Ins Owners0.92%
Ins Owner Change0%
Market Cap14.16M
Analysts80
Price Target1.02 (262.6%)
Short Float %2.05%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)27.62%
Min EPS beat(2)-6.56%
Max EPS beat(2)61.8%
EPS beat(4)2
Avg EPS beat(4)18.85%
Min EPS beat(4)-6.56%
Max EPS beat(4)61.8%
EPS beat(8)4
Avg EPS beat(8)12.44%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-83.33%
EPS NQ rev (1m)20%
EPS NQ rev (3m)83.33%
EPS NY rev (1m)10.89%
EPS NY rev (3m)79.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB 2.32
EV/EBITDA N/A
EPS(TTM)-2.32
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)-0.22
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS0
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -157.44%
ROE -210.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.45
Quick Ratio 3.45
Altman-Z -17.46
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.25%
EPS Next Y88.2%
EPS Next 2Y39.27%
EPS Next 3Y24.54%
EPS Next 5Y61.44%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.49%
OCF growth 3YN/A
OCF growth 5YN/A